Adults taking Mounjaro® with diet and exercise in a controlled clinical trial lost on average 21.8 kg. at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg) over a period of 72 weeks.1,2 Individual results may vary Mounjaro® delivered superior A1C reductions
Participants using tirzepatide lost 22.8 kg and participants on semaglutide lost 15.0 kg SURMOUNT-5 compared tirzepatide, a dual GIP and GLP-1 receptor agonist, to semaglutide, a mono GLP-1 receptor agonist in adults living with obesity without diabetes Eli Lilly and Company (NYSE: LLY) today announced topline results
A weekly injection of semaglutide was safe and reduced by 31% of liver fat in patients with HIV and liver disease-as per data from a mid-stage study presented by the National Institutes of Health showed. Data from the study was first released on Monday at the
